These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 21491995

  • 1. Metabolism and ocular tissue distribution of an antiglaucoma prostanoid, tafluprost, after ocular instillation to monkeys.
    Fukano Y, Kawazu K, Akaishi T, Bezwada P, Pellinen P.
    J Ocul Pharmacol Ther; 2011 Jun; 27(3):251-9. PubMed ID: 21491995
    [Abstract] [Full Text] [Related]

  • 2. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats.
    Fukano Y, Kawazu K.
    Drug Metab Dispos; 2009 Aug; 37(8):1622-34. PubMed ID: 19477946
    [Abstract] [Full Text] [Related]

  • 3. Benefits of Tafluprost and Timolol Fixed-Dose Combination for the Treatment of Glaucoma Are Confirmed by Studies on Experimental Animal Models.
    Akaishi T, Shimazaki A, Tonouchi A, Ueda K, Miyawaki N, Kawazu K.
    J Ocul Pharmacol Ther; 2015 Nov; 31(9):518-24. PubMed ID: 26325164
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography. Glaucoma Research Laboratories.
    Sjöquist B, Johansson A, Stjernschantz J.
    Arzneimittelforschung; 1999 Mar; 49(3):240-9. PubMed ID: 10219468
    [Abstract] [Full Text] [Related]

  • 5. Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination.
    Fuwa M, Ueda K, Akaishi T, Yamashita N, Kirihara T, Shimazaki A, Mano H, Kawazu K.
    PLoS One; 2016 Mar; 11(7):e0158797. PubMed ID: 27383260
    [Abstract] [Full Text] [Related]

  • 6. Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits.
    Tajika T, Isowaki A, Sakaki H.
    J Ocul Pharmacol Ther; 2011 Feb; 27(1):43-9. PubMed ID: 21118027
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.
    Takagi Y, Nakajima T, Shimazaki A, Kageyama M, Matsugi T, Matsumura Y, Gabelt BT, Kaufman PL, Hara H.
    Exp Eye Res; 2004 Apr; 78(4):767-76. PubMed ID: 15037111
    [Abstract] [Full Text] [Related]

  • 8. The use of the African green monkey as a preclinical model for ocular pharmacokinetic studies.
    Glogowski S, Ward KW, Lawrence MS, Goody RJ, Proksch JW.
    J Ocul Pharmacol Ther; 2012 Jun; 28(3):290-8. PubMed ID: 22235843
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: single intravenous, oral or topical administration on the eye.
    Sjöquist B, Tajallaei S, Stjernschantz J.
    Arzneimittelforschung; 1999 Mar; 49(3):225-33. PubMed ID: 10219466
    [Abstract] [Full Text] [Related]

  • 10. The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice.
    Ota T, Aihara M, Saeki T, Narumiya S, Araie M.
    Br J Ophthalmol; 2007 May; 91(5):673-6. PubMed ID: 17124244
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of latanoprost in the cynomolgus monkey. 2nd communication: repeated topical administration on the eye.
    Sjöquist B, Uhlin A, Byding P, Stjernschantz J.
    Arzneimittelforschung; 1999 Mar; 49(3):234-9. PubMed ID: 10219467
    [Abstract] [Full Text] [Related]

  • 12. Ocular hypotensive effect of tafluprost in latanoprost low-responder cynomolgus monkeys.
    Kurashima H, Asai Y, Aihara M, Ishida N, Nakamura M, Araie M.
    J Glaucoma; 2012 Feb; 21(2):123-8. PubMed ID: 21423041
    [Abstract] [Full Text] [Related]

  • 13. Ocular absorption, distribution, and systemic absorption of a novel antiglaucoma medication, prostaglandin derivative, in male white rabbits.
    Higaki K, Kamata K, Takeuchi M, Inazawa K, Chikai T, Hamaguchi T, Yukawa T, Kadono K, Kawahara S, Nakano M.
    Drug Metab Dispos; 1995 Jan; 23(1):35-43. PubMed ID: 7720522
    [Abstract] [Full Text] [Related]

  • 14. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye.
    Chastain JE, Sanders ME, Curtis MA, Chemuturi NV, Gadd ME, Kapin MA, Markwardt KL, Dahlin DC.
    Exp Eye Res; 2016 Apr; 145():58-67. PubMed ID: 26474497
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ocular pharmacokinetics of mapracorat, a novel, selective glucocorticoid receptor agonist, in rabbits and monkeys.
    Proksch JW, Lowe ER, Ward KW.
    Drug Metab Dispos; 2011 Jul; 39(7):1181-7. PubMed ID: 21441467
    [Abstract] [Full Text] [Related]

  • 18. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes.
    Acheampong AA, Shackleton M, John B, Burke J, Wheeler L, Tang-Liu D.
    Drug Metab Dispos; 2002 Apr; 30(4):421-9. PubMed ID: 11901096
    [Abstract] [Full Text] [Related]

  • 19. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans.
    Proksch JW, Granvil CP, Siou-Mermet R, Comstock TL, Paterno MR, Ward KW.
    J Ocul Pharmacol Ther; 2009 Aug; 25(4):335-44. PubMed ID: 19492955
    [Abstract] [Full Text] [Related]

  • 20. The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit.
    Sjöquist B, Basu S, Byding P, Bergh K, Stjernschantz J.
    Drug Metab Dispos; 1998 Aug; 26(8):745-54. PubMed ID: 9698288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.